Cytochromes P450 Inhibitory Excipient-Based Self-Microemulsions for the Improved Bioavailability of Protopanaxatriol and Protopanaxadiol: Preparation and Evaluation

Abstract

Protopanaxatriol and protopanaxadiol exhibit limited oral bioavailability due to the poor solubility and intestinal cytochromes P450-mediated metabolism. This study set out to develop a novel cytochromes P450 inhibitory excipient(s)-based self-microemulsion to encapsulate protopanaxatriol and protopanaxadiol so as to enhance the in vivo bioavailability by inhibiting intestinal metabolism. After screening the inhibitory effect of pharmaceutical excipients on the cytochromes P450-mediated metabolism, two self-microemulsions, SME-1 and SME-2, with similar physicochemical properties were prepared by using either active inhibitory excipients or corresponding inactive excipients. The results showed that no significant difference existed in the profiles of in vitro release, cellular uptake, and permeability in Caco-2 cells, and in vivo lymphatic transport between self-microemulsion-1 and self-microemulsion-2. The in vivo pharmacokinetic experiments indicated that self-microemulsion-1 conferred to significantly higher absolute bioavailability of protopanaxatriol (19.55 %) and protopanaxadiol (100.07 %) than those of the free drug (2.21 % and 23.70 %, respectively) or of self-microemulsion-2 (4.95 % and 45.35 %, respectively). The present work demonstrated that the presence of cytochromes P450 inhibitory excipients in self-microemulsion-1 tended to inhibit intestinal cytochromes P450-mediated metabolism and subsequently improved the oral bioavailability of protopanaxatriol and protopanaxadiol.

Key words

protopanaxatriol (PPT) - protopanaxadiol (PPD) - self-microemulsion - CYP450 - oral bioavailability

• References

• 1 Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999; 58: 1685-1693
• 2 Leung KW, Wong AS. Pharmacology of ginsenosides: a literature review. Chin Med 2010; 5: 20
• 3 Hasegawa H, Sung JH, Benno Y. Role of human intestinal Prevotella oris in hydrolyzing ginseng saponins. Planta Med 1997; 63: 436-440
• 4 Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci 2004; 95: 153-157
• 5 Sun L, Wang Q, Liu X, Brons NH, Wang N, Steinmetz A, Lv Y, Liao Y, Zheng H. Anti-cancer effects of 20(S)-protopanoxadiol on human acute lymphoblastic leukemia cell lines Reh and RS4; 11. Med Oncol 2011; 28: 813-821
• 6 Chen G, Yang M, Nong S, Yang X, Ling Y, Wang D, Wang X, Zhang W. Microbial transformation of 20(S)-protopanaxadiol by Absidia corymbifera. Cytotoxic activity of the metabolites against human prostate cancer cells. Fitoterapia 2013; 84: 6-10
• 7 Ren HC, Sun JG, Wang GJ, A JY. Xie HT, Zha WB, Yan B, Sun FZ, Hao HP, Gu SH, Sheng LS, Shao F, Shi J, Zhou F. Sensitive determination of 20(S)-protopanaxadiol in rat plasma using HPLC-APCI-MS: application of pharmacokinetic study in rats. J Pharm Biomed Anal 2008; 48: 1476-1480
• 8 Han MH, Chen J, Chen S, Wang X. Development of a UPLC-ESI-MS/MS assay for 20(S)-protopanaxadiol and pharmacokinetic application of its two formulations in rats. Anal Sci 2010; 26: 749-753
• 9 Li L, Chen XY, Li D, Zhong DF. Identification of 20(S)-protopanaxadiol metabolites in human liver microsomes and human hepatocytes. Drug Metab Dispos 2011; 39: 472-483
• 10 Xie FY, Li SW, Cheng ZN, Liu XL, Zhang H, Li PJ, Liu Z, Guo X, Yu P. Determination of 20(S)-protopanaxadiol in human plasma by HPLC-MS/MS: application to a pharmacokinetic study. Acta Pharm Sin B 2013; 3: 385-391
• 11 Kong LT, Wang Q, Xiao BX, Liao YH, He XX, Ye LH, Liu XM, Chang Q. Different pharmacokinetics of the two structurally similar dammarane sapogenins, protopanaxatriol and protopanaxadiol, in rats. Fitoterapia 2013; 86: 48-53
• 12 Jin X, Zhang ZH, Sun E, Tan XB, Xia HJ, Liu QY, Jia XB. [Polybasic research on the biopharmaceutical characteristics of 20(S)-protopanaxadiol]. Yao Xue Xue Bao 2013; 48: 411-416
• 13 Jin X, Zhang ZH, Li SL, Sun E, Tan XB, Song J, Jia XB. A nanostructured liquid crystalline formulation of 20(S)-protopanaxadiol with improved oral absorption. Fitoterapia 2013; 84: 64-71
• 14 Han MH, Ma LQ, Yu X, Li ZT, Guo YF, Wang XT. A nanoparticulate drug-delivery system for 20(S)-protopanaxadiol: formulation, characterization, increased oral bioavailability and anti-tumor efficacy. Drug Deliv 2015; 25: 1-9
• 15 Chen C, Wang LS, Cao FR, Miao XQ, Chen TK, Chang Q, Zheng Y. Formulation of 20(S)-protopanaxadiol nanocrystals to improve oral bioavailability and brain delivery. Int J Pharm 2016; 497: 239-247
• 16 Wang B, Pu Y, Xu B, Tao J, Wang Y, Zhang T, Wu P. Self-microemulsifying drug delivery system improved oral bioavailability of 20(S)-protopanaxadiol: from preparation to evaluation. Chem Pharm Bull (Tokyo) 2015; 63: 688-693
• 17 Xia HJ, Zhang ZH, Jin X, Hu Q, Chen XY, Jia XB. A novel drug-phospholipid complex enriched with micelles: preparation and evaluation in vitro and in vivo . Int J Nanomedicine 2013; 8: 545-554
• 18 Hao H, Lai L, Zheng C, Wang Q, Yu G, Zhou X, Wu L, Gong P, Wang G. Microsomal cytochrome p450-mediated metabolism of protopanaxatriol ginsenosides: metabolite profile, reaction phenotyping, and structure-metabolism relationship. Drug Metab Dispos 2010; 38: 1731-1739
• 19 Chiu NT, Tomlinson Guns ES, Adomat H, Jia W, Deb S. Identification of human cytochrome P450 enzymes involved in the hepatic and intestinal biotransformation of 20(S)-protopanaxadiol. Biopharm Drug Dispos 2014; 35: 104-118
• 20 Jin X, Zhang ZH, Sun E, Tan XB, Li SL, Cheng XD, You M, Jia XB. Enhanced oral absorption of 20(S)-protopanaxadiol by self-assembled liquid crystalline nanoparticles containing piperine: in vitro and in vivo studies. Int J Nanomedicine 2013; 8: 641-652
• 21 Ren X, Mao X, Cao L, Xue K, Si L, Qiu J, Schimmer AD, Li G. Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo . Eur J Pharm Sci 2009; 36: 401-411
• 22 Kim AR, Lim SJ, Lee BJ. Metabolic inhibition and kinetics of raloxifene by pharmaceutical excipients in human liver microsomes. Int J Pharm 2009; 368: 37-44
• 23 Argikar UA, Liang G, Bushee JL, Hosagrahara VP, Lee W. Evaluation of pharmaceutical excipients as cosolvents in 4-methyl umbelliferone glucuronidation in human liver microsomes: applications for compounds with low solubility. Drug Metab Pharmacokinet 2011; 26: 102-106
• 24 Zhou J, Zhou M, Yang FF, Liu CY, Pan RL, Chang Q, Liu XM, Liao YH. Involvement of the inhibition of intestinal glucuronidation in enhancing the oral bioavailability of resveratrol by labrasol containing nanoemulsions. Mol Pharm 2015; 12: 1084-1095
• 25 Wu X, Xu J, Huang X, Wen C. Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability. Drug Dev Ind Pharm 2011; 37: 15-23
• 26 Amri A, Le Clanche S, Thérond P, Bonnefont-Rousselot D, Borderie D, Lai-Kuen R, Chaumeil JC, Sfar S, Charrueau C. Resveratrol self-emulsifying system increases the uptake by endothelial cells and improves protection against oxidative stress-mediated death. Eur J Pharm Biopharm 2014; 86: 418-426
• 27 Weerapol Y, Limmatvapirat S, Kumpugdee-Vollrath M, Sriamornsak P. Spontaneous emulsification of nifedipine-loaded self-nanoemulsifying drug delivery system. AAPS PharmSciTech 2015; 16: 435-443
• 28 Gupta S, Kesarla R, Omri A. Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharm 2013; 2013: 848043